Genetic Variation in NPC1L1 and Risk of Gallstone Disease.

We read with great interest the recent paper by Ference et al. (1) using genetic variants in NPC1L1 (target for ezetimibe) and HMGCR (target for statins) to predict the effect of ezetimibe and statins on low-density lipoprotein (LDL) cholesterol and risk of coronary heart disease. Ezetimibe reduces plasma levels of LDL cholesterol by inhibiting Niemann-Pick… CONTINUE READING